Geneseeq has introduced an innovative multi-cancer early detection solution known as CanScan™, marking a significant advancement in the field.
CanScan™ utilises a novel approach by employing low-depth whole-genome sequencing (WGS) on circulating cell-free DNA (cfDNA) obtained from a single tube of peripheral blood.
By analysing genetic and fragmentomic features, CanScan™ can detect early signals of cancer with an impressive specificity of 99 percent while also predicting the tissue of origin (TOO) of the cancer. This predictive capability aids in guiding subsequent steps for cancer diagnosis and treatment.
The introduction of CanScan™ holds great promise in addressing existing gaps in clinical diagnosis and treatment, particularly among individuals aged 50 and above with an average risk of cancer.
Notably, this test outperforms current standard screening methods for common cancer types like prostate, lung, and liver cancers. Furthermore, it can identify cancer types that lack effective screening methods, such as esophageal, endometrial, gastric, pancreatic cancers, and lymphoma.
Developed using the highly sensitive MERCURY™ multi-omics technology, CanScan™'s performance has undergone validation through a comprehensive clinical study series called DECIPHER (Detecting Early Cancer by Inspecting ctDNA Features), covering over thirteen cancer types.
US Food and Drug Administration (FDA) has granted breakthrough device designation for CanScan™.
